

Describing COVID-19 Patients During The First Two Months of Paxlovid (Nirmatrelvir/Ritonavir) Initiation in a Large HMO in Israel

Lilac Tene, MSc¹
Gabriel Chodick, PhD¹
Noga Fallach, MSc¹
Wajeeha Ansari, MPH²
Tal Distelman-Menachem, PhD³
Yasmin Maor, MD⁴

¹ Maccabi Healthcare Services (MHS), Israel

² Pfizer Inc., USA

³ Pfizer, Israel

⁴ Infectious Disease Unit, Wolfson Medical Center, and Faculty of Medicine, Tel Aviv University, Israel

May 2, 2022

Abstract

Title

Describing COVID-19 Patients During The First Two Months of Paxlovid (Nirmatrelvir/Ritonavir) Initiation in a Large HMO in Israel

Objective

The objective of this feasibility study was to assess the number of patients that could be included in a future Real World Evidence study, which would be designed to explore the impact of Paxlovid (nirmatrelvir/ritonavir) on patient outcomes and healthcare resource utilization (HCRU). We also intend to assess the comparability of the patients who were treated with Paxlovid versus patients who did not receive the treatment, either because they declined any COVID-19 treatment or were diagnosed with COVID-19 prior to Paxlovid availability.

Methods

This retrospective observational secondary data study used data from the Maccabi Healthcare Services database during the identification period of June 1, 2021, to February 28, 2022. The study population included patients with at least one positive SARS-CoV-2 RT-PCR test, or a formal rapid antigen test for SARS-CoV-2, during the identification period, the date of which also served as the COVID-19 diagnosis date. We then divided the study population into the following cohorts: Pre-Paxlovid Time Period and Paxlovid Time Period, which was further split into Paxlovid Treated and Paxlovid Untreated.

Results

Application of inclusion and exclusion criteria to the study population rendered 20,284 patients in the Pre-Paxlovid Time Period cohort and 5,542 in the Paxlovid Time Period cohort that were eligible to receive Paxlovid. This resulted in 3,714 in the Paxlovid Treated and 1,810 in the Paxlovid Untreated cohorts.

Conclusions

This RWE feasibility study of patients with a positive test for COVID-19 between June 1, 2021 to February 28, 2022 illustrates potential comparability between cohorts, as described by their demographics and characteristics.

Acknowledgements

The authors thank Joanna Atkinson, Griffith Bell, Michael Benigno, Birol Emir, Amie Scott, of Pfizer Inc, for their support in the study design and their contributions to this paper. The authors also thank Arnon Shahar and Shirley Shapiro Ben-David, of Maccabi Healthcare Services, for their contributions to this paper. This study was sponsored by Pfizer Inc. Medical writing support was provided by Yasmin Maor, MD of Tel Aviv University and was funded by Maccabi Healthcare Services.

Conflicts of Interest

Funding

This study was conducted as a collaboration between Maccabi Healthcare Services and Pfizer. Maccabi Healthcare Services is the study sponsor.

Background & Feasibility Objectives

The COVID-19 pandemic, caused by SARS-CoV-2, resulted in more than 6.1 million deaths worldwide as of April 4, 2022.¹ SARS-CoV-2 may lead to severe acute respiratory syndrome, resulting in hospitalizations, intensive care unit (ICU) stays, and receipt of invasive mechanical ventilation (IMV). Patients at high risk for progression to severe disease (i.e., hospitalization) include unvaccinated individuals, adults ≥ 65 years, current smokers, and those with certain underlying medical conditions including renal disease, chronic lung disease, cardiovascular disease, neurological disorders, and diabetes.² Until recently, treatment options for COVID-19 patients were limited, and most were given in a hospital setting. Treatments in the early phase of the disease relied primarily on convalescent plasma and monoclonal and bi-clonal antibodies administered by injections or intravenously.^{3,4} In particular, no orally available drugs were available to prevent the deterioration of high-risk patients.

On December 22, 2021, the US Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for a new COVID-19 antiviral, PAXLOVID™ (nirmatrelvir [PF-07321332]/ritonavir). Nirmatrelvir is an orally administered antiviral agent targeting the SARS-CoV-2 3-chymotrypsin-like cysteine protease enzyme (Mpro) essential for viral replication.⁵ Nirmatrelvir is metabolized mainly by CYP3A4, thus co-administration with ritonavir, a CYP3A4 inhibitor, enhances nirmatrelvir pharmacokinetics.^{6,7} EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) was a randomized, double-blind study of 2,246 non-hospitalized, symptomatic, unvaccinated adult patients with COVID-19, who were at high risk of progressing to severe illness. The trial analysis showed an 89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placebo in patients treated within three days of symptom onset. A similar relative risk reduction of 88% was obtained in a subgroup analysis including patients receiving treatment within five days of symptom onset. Paxlovid also demonstrated a tolerable safety profile.⁸

Maccabi Healthcare Services (MHS) is the second largest health maintenance organization (HMO) in Israel, caring for more than 2.5 million people. Paxlovid became available to eligible MHS members on January 2, 2022. The effectiveness of Paxlovid in terms of morbidity, mortality, and its impact on healthcare resource utilization (HCRU) has yet to be assessed using real world evidence (RWE).

The objective of this feasibility study was to assess the number of patients that could be included in a future RWE study, which would be designed to explore the impact of Paxlovid on patient outcomes and healthcare resource utilization (HCRU). We also intend to assess the comparability of the patients who were treated with Paxlovid in MHS versus patients who did not receive the treatment,

either because they declined any COVID-19 treatment or were diagnosed with COVID-19 prior to Paxlovid availability.

Methods

Study Design

This retrospective observational secondary data study used data from the MHS database and we identified patients during the period of June 1, 2021, to February 28, 2022 (N=2,540,691), as described in [Figure 1](#).

MHS is a nationwide health plan (payer-provider) representing a quarter of the population in Israel. The MHS database contains longitudinal data on a stable population of >2.5 million people since 1993 (with <1%/year moving out). Computerized registries of several chronic diseases were developed by MHS and are continuously updated. As a state-mandated health provider and insurer, MHS covers by law all hospitalizations in general hospitals outside the MHS network, as well as visits to urgent care center and ER in hospitals (including cases where a co-pay is required).

Patients' data are retrieved from MHS medical electronic files and include sociodemographic details, co-morbidities according to ICD-9 codes, immunocompromised registry eligibility, dates of all SARS-CoV-2 PCR tests and formal antigen tests, concomitant medications, hospitalization, and death. COVID-19 symptoms were collected from MHS patients via a questionnaire.

Study Population

To identify the study population, we included only patients with at least one positive SARS-CoV-2 RT-PCR test, or a formal rapid antigen test for SARS-CoV-2, during the identification period (N=845,750), the date of which also served as the COVID-19 diagnosis date. We divided these patients into the following cohorts:

1. **Pre-Paxlovid Time Period:** Patients in the period when Paxlovid was not available in Israel and Delta was the dominant circulating variant (June 1, 2021, to November 30, 2021, N=207,115)⁹
2. **Paxlovid Time Period:** Patients in the time period when Paxlovid was available in Israel (January 2, 2022, to February 28, 2022, N=638,635), which was then further subdivided into:
 - a. **Paxlovid Treated:** patients with a SARS-CoV-2 infection who received Paxlovid treatment

- b. **Paxlovid Untreated:** patients with a SARS-CoV-2 infection who were offered Paxlovid and declined Paxlovid or any other COVID-19 treatment

For patients in the **Paxlovid Treated** cohort, the index date was defined as the date of first dispensed Paxlovid. For patients in the **Paxlovid Untreated** cohort, the index date was defined as the date that Paxlovid treatment was declined.

For patients in the **Pre-Paxlovid Time Period**, the index date was defined using the average number of days from the first positive SARS-CoV-2 test to Paxlovid dispensed date in the **Paxlovid Treated** cohort. The number of days obtained from this calculation was added to the date of the **Pre-Paxlovid Time Period** patients' first SARS-CoV-2 RT-PCR, or formal antigen positive test.

Eligibility

To be eligible to receive Paxlovid in Israel, patients have to be aged 70 years or older regardless of risk score (as defined below); aged 50 to 69 years and have a risk score of 2 points or more; or aged 12-49 years with a risk score of four points or more.

Patients were excluded if they were hospitalized prior to Paxlovid treatment or on the index date, received an additional positive PCR or formal rapid antigen test for SARS-CoV-2 in the six months prior to the index date, received Paxlovid prior to a registered SARS-CoV-2 positive test, were found ineligible to receive Paxlovid, received any other approved COVID-19 treatment, or received Paxlovid more than five days after diagnosis.

Risk Score Calculation

MHS utilizes a COVID-19 Risk Score point system that combines age and characteristics for a numeric score ranging from 0 to 4, where 4 represents highest risk of progression to severe COVID-19. To be eligible to receive Paxlovid patients had to be aged 70 years or more regardless of risk score; aged 50 to 69 years and have a risk score of 2 points or more; or aged 12-49 years with a risk score of four points or more. Each of the following characteristics contributed one point to the risk score: BMI ≥ 30 kg/m²; diabetes mellitus; cardiovascular disease (CVD); chronic kidney disease (CKD); chronic liver disease; neurologic disease; active malignancy or malignancy treated during the past 5 years; Immunosuppression (See [Figure 2](#)); hospitalization in the past 3 years (not including delivery/birth).

Statistical Analyses

In this descriptive feasibility study, we explored patients' data at index date to see if it would be suitable for further analysis. We described continuous variables using summary statistics such as mean, median standard deviation and interquartile range. We also examined lowest and highest

observations of each variable to ensure that the data were within plausible ranges. For categorical and binary variables, we calculated counts (missing values and non-missing) and percentages. We calculated the standardized differences (SD) for the continuous and categorical variables.¹⁰ SD greater than .10 in absolute value suggested potentially meaningful differences. As the purposes of this study were description and feasibility for future study, no formal hypothesis testing was performed. All data analysis was performed by Maccabi Healthcare Services using Statistical Software – SAS v9.4.

Results

Study Population Size

In the study population, we identified patients, aged 12 years or older on the index date, that were eligible to receive Paxlovid, as defined by age and their risk score. This rendered 20,284 patients in the **Pre-Paxlovid Time Period** and 10,030 in the **Paxlovid Time Period** that were eligible to receive Paxlovid (**Figure 1**).

To further refine the patients included in the **Paxlovid Time Period** cohort, we applied our exclusion criteria, which resulted in 5,542 patients. Of these, we also excluded an additional 18 patients because they received Paxlovid more than five days after diagnosis.

We then divided patients in the **Paxlovid Time Period** into **Paxlovid Treated** (N=3,714) and **Paxlovid Untreated** (N=1,810) cohorts.

Characteristics of Study Population

Table 1 describes the demographics and clinical characteristics of the study population as well as their associated standardized differences.

The proportion of unvaccinated patients was lowest in the **Paxlovid Treated** cohort (9.8%) and similar in the **Paxlovid Untreated** (25.9%) and **Pre-Paxlovid Time Period** (22.9%) cohorts. Most patients had no record of previous COVID-19 infections. The mean time from positive COVID-19 test to treatment was 1.8 days.

The number of patients with a COVID-19 Hospital Risk Score of 4 was highest in the **Paxlovid Untreated** cohort at 87.2%, followed by 69% in the **Paxlovid Treated** and 64.7% in the **Pre-Paxlovid Time Period** cohorts. While some risk conditions varied among the cohorts (e.g., hypertension and CKD being higher in the **Paxlovid Untreated** vs. **Paxlovid Treated**), most were similar, with the **Pre-Paxlovid Time Period** cohort having the lowest frequency of risk conditions.

Most patients reported experiencing at least one COVID-19 symptom across all three cohorts (**Treated:** 74%, **Untreated:** 64%, and **Pre-Paxlovid:** 81%). Of note, fever and cough were less common in the **Paxlovid Untreated** cohort (27.7% and 45%) versus the **Paxlovid Treated** (35.5% and 56.4%) and the **Pre-Paxlovid Time Period** cohort (80.6% and 45%). On the other hand, anosmia was more common in the **Pre-Paxlovid Time Period** cohort (17.8%) compared to the **Paxlovid Treated** (3%) and **Paxlovid Untreated** (2.7%) cohorts.

Paxlovid Treated patients had higher (7-10) SES scores (61.2%) compared to **Paxlovid Untreated** (47.1%).

In terms of age, the **Paxlovid Time Period** cohorts were generally older than the **Pre-Paxlovid Time Period** cohort (66.8 vs. 58.4 on average). The percentage of patients in the ≥ 70 years age group were higher in the **Paxlovid Treated** (66.8 and 43.3%) and **Paxlovid Untreated** (67.1 and 47.8%) cohorts compared to the **Pre-Paxlovid Time Period** cohort (58.4 and 16.1%). Characteristics associated with an increased risk were similar across cohorts for smoking status and BMI.

Discussion

The patient population authorized for treatment in Israel differs from the patient population described in the study by Hammond et al.⁸ Paxlovid was authorized for use in Israel for vaccinated and unvaccinated patients, while the trial only included unvaccinated patients. In addition, the Omicron variant was dominant at the time when Paxlovid became available in Israel, while Delta was the dominant variant when the study by Hammond et al. was performed.⁸ These and other differences in the patient population, timing of treatment, and exposure to SARS-CoV-2 in past and present may impact the real world experience of Paxlovid treatment.

This RWE feasibility study of patients with a positive test for COVID-19 between June 1, 2021 to February 28, 2022 illustrates potential comparability between cohorts, as described by their demographics and characteristics.

When comparing the **Paxlovid Treated** cohort to the **Paxlovid Untreated** cohort, the **Paxlovid Treated** cohort had a higher socioeconomic status score, and a lower risk score for progression to severe COVID-19. They were also more likely to be vaccinated and had a shorter interval from the index date and previous vaccine dose. The two groups were similar in their associated comorbidities and number of previous hospitalizations.

Among the three cohorts, the **Paxlovid Treated** and the **Paxlovid Time Period** cohorts were the most different. Patients in the **Pre-Paxlovid Time Period** cohort were younger, had a lower SES score, had

a lower BMI, and fewer comorbidities. They also had a lower vaccination rate and a longer time between the last vaccine dose and the index date. These differences may be a result of different health seeking behaviors between the two groups as possibly represented by vaccine acceptance.

Data regarding Paxlovid Time Period patients is still scarce and only few preliminary reports were published comparing patients diagnosed with Omicron and Delta variants. A retrospective cohort study of a large, geographically diverse database of patient electronic health records in the US demonstrated that the monthly incidence rate of COVID-19 infections was 0.5-0.7 when Delta dominated, and rapidly increased to 3.8-5.2 when Omicron dominated.¹¹ After propensity-score matching, the risks for severe clinical outcomes in the Omicron cohort were significantly lower than in the Delta cohort. This study did not consider the vaccination status of the study population. Another study assessing patients with COVID-19 in the US demonstrated that a higher proportion of adults admitted during Omicron were fully vaccinated (39.6% versus 25.1%), and fewer received COVID-19-directed therapies when compared to the Delta-dominant period. Fewer fully vaccinated Omicron-dominant period patients died while hospitalized (3.4%) compared with Delta-dominant period patients (10.6%).¹² The likelihood of ICU admission and death were lowest among adults who had received a booster vaccine dose. Thus the differences seen among the three cohorts in our study are expected and not unique to our cohort.

While it appears a control group for a future RWE study could be identified, additional exclusions or statistical adjustments may be needed to compare patient outcomes. This feasibility supports future analyses by identifying key characteristics needed for future comparisons.

Figures & Tables

Figure 1. Study flowchart




Figure 2. Criteria for inclusion in the MHS immunosuppression registry




Table 1. Demographics and Clinical Characteristics

Characteristics	Paxlovid Treated cohort (Jan 1 - Feb 28, 2022) N = 3,714		Paxlovid Untreated cohort (Jan 1 - Feb 28, 2022) N = 1,810		SD* Between Treated vs. Untreated	Pre-Paxlovid Time Period cohort (June 1 - Nov 30, 2021) N = 20,284		SD* Between Treated vs. Untreated
	N/Stat 1	%/Stat 2	N/Stat 1	%/Stat 2		N/Stat 1	%/Stat 2	
Age numeric					-0.02			0.73
Mean/Std	66.8	11.9	67.1	13.7		58.4	11.1	
N/Missing Values	3,714	0	1,810	0		20,282	0	
Lowest/Highest	19	103	18	100		13	109	
First/Third Quartile	59	75	59	76		51	65	
Median/IQR	67	59-75	69	59-76		56	51-65	
Age group, N (%)					0.21			0.64
≤49 years	219	5.9	182	10.1		2,810	13.9	
50-69 years	1,888	50.8	762	42.1		14,206	70.0	
≥70 years	1,607	43.3	866	47.8		3,268	16.1	
Gender, N (%)					-0.01			-0.03
Female	1,845	49.7	902	49.8		10,350	51.0	
Male	1,869	50.3	908	50.2		9,934	49.0	
Population subgroup, N (%)					-0.00			0.20
Ultra-orthodox Jewish	217	5.8	132	7.3		1767	8.7	
Jewish	3439	92.6	1614	89.2		17647	87.0	
Arab	58	1.6	64	3.5		870	4.3	
SES score, N (%)					0.29			0.32
Low (1-4)	643	17.3	461	25.5		5695	28.1	
Medium (5-6)	761	20.5	469	25.9		4918	24.2	
High (7-10)	2272	61.2	852	47.1		9383	46.3	
Missing	38	1.0	28	1.5		288	1.4	
Smoking status, N (%)					-0.09			-0.06
Never smoker	2851	76.8	1326	73.3		14909	73.5	
Ever	827	22.3	473	26.1		4987	24.6	
Unknown	36	1.0	11	0.6		388	1.9	
BMI, kg/m² numeric					0.05			0.17
Mean/Std	28.9	5.6	28.7	5.4		28.0	5.3	
N/Missing Values	3660	54	1790	20		19728	556	
Lowest/Highest	11.8	60.7	15.8	61.0		8.9	67.2	
First/Third Quartile	25.1	31.9	24.8	31.9		24.3	30.9	
Median/IQR	28.1	25.1-31.9	28.0	24.8-31.9		27.3	24.3-30.9	
COVID-19 Hospital risk score, N (%)					0.45			0.28
1	0	0	0	0		0	0	
2	21	0.6	3	0.2		1076	5.3	
3	1130	30.4	229	12.7		6060	29.9	
4	2563	69	1578	87.2		13120	64.7	
Unknown	0	0	0	0		28	0.1	
Chronic diseases and risk conditions, N (%)					0.00			0.13
BMI ≥ 30 kg/m ² (obesity)	1342	36.1	656	36.2		6065	29.9	

Diabetes mellitus	1224	33	641	35.4	-0.05	3398	16.8	0.38
Cardiovascular disease (CVD)	826	22.2	409	22.6	-0.01	1917	9.5	0.36
Hypertension	2158	58.1	1147	63.4	-0.11	6960	34.3	0.49
Chronic kidney disease (CKD)	651	17.5	431	23.8	-0.16	1676	8.3	0.28
Liver disease	908	24.4	422	23.3	0.03	3581	17.7	0.17
Diseases of the nervous system (ICD-9)	290	7.8	137	7.6	0.00	1148	5.7	0.14
COPD	297	8	139	7.7	0.01	584	2.9	0.23
Cancer (active or treated prior 5-years)	857	23.1	361	19.9	0.08	2247	11.1	0.32
Immunosuppressed	451	12.1	227	12.5	-0.01	1068	5.3	0.25
Hospitalization in prior 3-years	1718	46.3	851	47	-0.02	6723	33.1	0.27
Symptoms reported to PCP								
Any symptoms	2738	73.7	1157	63.9	0.21	16352	80.6	-0.16
Fever	1318	35.5	502	27.7	0.17	8654	42.7	-0.15
Cough	2093	56.4	815	45	0.23	9121	45.0	0.23
Dyspnea	289	7.8	92	5.1	0.11	1375	6.8	0.04
Diarrhea	134	3.6	59	3.3	0.02	1109	5.5	-0.09
Anosmia	111	3	49	2.7	0.02	3601	17.8	-0.50
Myalgia	1099	29.6	436	24.1	0.12	6010	29.6	-0.00
Weakness	6	0.2	3	0.2	-0.00	3117	15.4	-0.59
Other	1302	35.1	510	28.2	0.15	9547	47.1	-0.25
Time from positive COVID-19 test to treatment (days)								
Mean/Std	1.8	0.9						
N/Missing Values	3714	0						
Lowest/Highest	1	5						
First Quartile/Third Quartile	1	2						
Median/IQR	2	1-2						
Covid-19 vaccination status								
Unvaccinated	363	9.8	468	25.9	0.45	4641	22.9	NA**
One dose	57	1.5	38	2.1		254	1.3	
Two doses	175	4.7	89	4.9		11862	58.5	
Three doses	1895	51	810	44.8		3527	17.4	
More than three doses	1224	33	405	22.4		0	0	
Covid-19 vaccination and previous infection, N (%)								
Unvaccinated with no previous infection	357	9.6	461	25.5	0.43	4506	22.2	0.36
Unvaccinated with previous infection	6	0.2	7	0.4		135	0.7	
Vaccinated with no previous infection	3332	89.7	1327	73.3		15561	76.7	
Vaccinated with previous infection	19	0.5	15	0.8		82	0.4	
Time since last vaccination, if vaccinated (days)								
Mean/Std	118.6	83.2	132.1	84.1	-0.16	147.5	74.4	-0.37

N/Missing Values	3351	363	1342	468		15643	4641	
Lowest/Highest	1	412	2	397		2	314	
First Quartile/Third Quartile	33	173	40	183		118	198	
Median/IQR	151	33-173	158	40-183		179	118-198	
Previous infection with Covid-19, N (%)								
Yes	108	2.9	103	5.7	0.00	217	1.1	0.00
No	3606	97.1	1707	94.3		20067	98.9	
Unknown	0	0	0	0		0	0	

*STD greater than .10 in absolute value suggests potentially meaningful differences

**NA - 4th vaccine was not available pre Paxlovid so SMD not calculated

References

1. WHO. WHO Situational Report. 2022. <https://covid19.who.int> (accessed April 11 2022).
2. CDC. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. February 15 2022. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/underlyingconditions.html> (accessed April 26 2022).
3. Maor Y, Cohen D, Paran N, et al. Compassionate use of convalescent plasma for treatment of moderate and severe pneumonia in COVID-19 patients and association with IgG antibody levels in donated plasma. *EClinicalMedicine* 2020; **26**: 100525.
4. Miguez-Rey E, Choi D, Kim S, Yoon S, Sandulescu O. Monoclonal antibody therapies in the management of SARS-CoV-2 infection. *Expert Opin Investig Drugs* 2022; **31**(1): 41-58.
5. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. *Science* 2003; **300**(5626): 1763-7.
6. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19. *Science* 2021; **374**(6575): 1586-93.
7. Sevrioukova IF, Poulos TL. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. *Proc Natl Acad Sci U S A* 2010; **107**(43): 18422-7.
8. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *New England Journal of Medicine* 2022.
9. MOH I. The COVID-19 Center for National Information and Knowledge. 2022. <http://datadashboard.health.gov.il>.
10. Yang D, Dalton JE. A unified approach to measuring the effect size between two groups using SAS®. SAS global forum; 2012; 2012. p. 1-6.
11. Wang L, Berger NA, Kaelber DC, Davis PB, Volkow ND, Xu R. COVID infection rates, clinical outcomes, and racial/ethnic and gender disparities before and after Omicron emerged in the US. *medRxiv* 2022.
12. Modes ME, Directo MP, Melgar M, et al. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(6): 217-23.